Inmune Bio, Inc. 8-K

What Happened

• Inmune Bio, Inc. filed a Current Report on Form 8‑K dated February 27, 2026 to disclose under Regulation FD that it has prepared an investor presentation (the “Presentation”).
• The Presentation is furnished as Exhibit 99.1 to the 8‑K and the filing also includes the cover page interactive data file as Exhibit 104 (Item 9.01).

Key Details

• Filing date: February 27, 2026 (8‑K disclosure under Item 7.01 — Regulation FD Disclosure).
• Exhibit 99.1: Investor Presentation slide deck furnished with the report.
• Exhibit 104: Cover Page Interactive Data File (Inline XBRL).
• The filing supplies the deck for use in company presentations “from time to time”; it does not report earnings, executive changes, or other corporate transactions.

Why It Matters

• The furnished investor presentation is an official, public source of company messaging and may include updates on strategy, pipeline, clinical programs, or metrics — investors should review the slides for any material operational or clinical information.
• This 8‑K is a disclosure of presentation materials under Regulation FD, not a substitute for an earnings release or formal financial report; any material financial results or corporate changes would be reported in separate filings.